Novamind Inc.
21.7.2021 14:02:56 CEST | ACCESS Newswire | Press release
Aims to increase visibility and facilitate investment for United States investors
TORONTO, ON / ACCESSWIRE / July 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has submitted its application to have its common shares posted for trading on the OTCQB® Venture Market (the "OTCQB"), a U.S. trading platform operated by the OTC Markets Group, Inc. The Company has also applied for Depository Trust Company (DTC) eligibility which would greatly simplify the process of trading the Company's common shares.
The posting of the Company's common shares for trading on the OTCQB remains subject to the approval of the OTC Markets Group, Inc. and the satisfaction of applicable eligibility requirements. The Company currently trades and will continue to trade on the Canadian Securities Exchange ("CSE") under its existing symbol "NM" and on the Frankfurt Stock Exchange ("FSE") under its existing symbol "HN2".
"Having the Company's common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind's mental health and psychedelic medicine business," said Yaron Conforti, CEO and Director of Novamind.
The OTCQB offers investors transparent trading in entrepreneurial and development stage U.S. and international companies that may not yet qualify for OTCQX. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
About OTC Markets Group
OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca
Disclaimer
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements relating to the common shares of the Company being posted for trading on the OTCQB and other statements that are not historical facts. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the failure to satisfy the requirements of the OTCQB and other risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
SOURCE: Novamind Inc.
View source version on accesswire.com:
https://www.accesswire.com/656418/Novamind-Has-Applied-to-Have-its-Common-Shares-Posted-for-Trading-on-the-OTCQB-in-the-United-States
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 2518.6.2026 15:00:00 CEST | Press release
As global leaders move from firefighting to foresight, OMP celebrates the enterprise visionaries scaling decision-driven intelligence at the speed of change. ANTWERPEN, BE / ACCESS Newswire / June 18, 2026 / OMP, a leading AI-powered provider of supply chain planning solutions, extends its congratulations to the 9 customer organizations recognized in the newly released Gartner® Supply Chain Top 25 and Masters for 2026. Now in its 22nd year, the Gartner Supply Chain Top 25 remains the definitive benchmark for supply chain excellence, evaluating global enterprises on financial performance, ESG initiatives, and community opinion. This year's rankings point to three capabilities separating market leaders: building an autonomous workforce where people and intelligent systems collaborate on decisions, adopting network-centric strategies that treat supply chain design as a continuous, adaptive process, and orchestrating decisions end-to-end across increasingly complex ecosystems. OMP's custom
U.S. Polo Assn. Unveils Spring-Summer 2027 Collection at the 110th Edition of Pitti Immagine Uomo18.6.2026 13:00:00 CEST | Press release
Global Sports Brand Puts the Iconic Polo Shirt at the Center of its Pitti Uomo Experience FLORENCE, IT AND WEST PALM BEACH, FL / ACCESS Newswire / June 18, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned to Florence, Italy, for Pitti Immagine Uomo 110 to present The Polo Shirt: An Icon Born from the Game™ and its Spring-Summer 2027 Global Collection showcasing a modern, global expression of the sport-inspired lifestyle. The collection includes classic, sport-inspired apparel, footwear, bags, and accessories that blend authentic American-inspired sports style with European craftsmanship. 1) Polo Shirt Installation for U.S. Polo Assn. Booth at Pitti Uomo 110 in Florence, Italy 2) U.S. Polo Assn. Booth at Pitti Uomo 110 featuring The Polo Shirt: An Icon Born from the Game 3) Pitti Uomo 110 Attendees Crowd the U.S. Polo Assn. Booth U.S. Polo Assn.'s exhibit at Pitti Uomo is taking place from June 16 to 19, 2026, at Booth 32 Cavanigli
Deadline Extended for 2026 Semmelweis-Richter Journalism Award Applications18.6.2026 11:30:00 CEST | Press release
Following strong interest and numerous requests, the application deadline for the 2026 Semmelweis-Richter Journalism Award has been extended by two weeks. Submissions are now accepted until June 23, 2026, 23:59 CET. BUDAPEST, HU / ACCESS Newswire / June 18, 2026 / Building on the success of its inaugural edition, the award continues to recognise outstanding journalism that contributes to public understanding of key health issues and fosters informed discussion across Europe. The initiative is organised by Semmelweis University, Hungary's leading medical and health sciences institution, in partnership with Gedeon Richter, a Hungary-based, innovation-driven specialty pharmaceutical company. Entries are invited in two categories: Women's Health and Pharmaceutical Strategies and Innovation, the latter placing particular emphasis on cardiovascular therapies. The organisers welcome high-quality reporting that sheds light on pressing or underrepresented health topics, addresses stigma, and su
LiberNovo Announces Early Launch of Prime Sale, Featuring Limited Omni Bundle Flash Deals Starting Today18.6.2026 04:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 17, 2026 / LiberNovo today opened early access to its 2026 Prime Sale, with up to 49% off and a limited run of flash-deal bundles built around the original LiberNovo Omni. Early access is live now, and the full sale runs June 23 through July 11. LiberNovo makes dynamic ergonomic chairs, the first designed to respond to your body as it moves. Instead of locking you into one fixed posture, the dynamic support system keeps the neck support, backrest, armrests, and seat moving together as you shift, lean, and recline. Prime Sale - Omni Series Clearance Deals The original LiberNovo Omni is available at Prime Sale clearance pricing while stocks last, with prices starting as low as €939 (49% off in the EU) and £869 (46% off in the UK), representing significant savings for consumers. The original LiberNovo Omni - the first dynamic ergonomic chair - features an eight-panel Bionic FlexFit Backrest and automatic armrests that move with you through every shif
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom